Minoru Kidokoro

Summary

Affiliation: National Institute of Infectious Diseases
Country: Japan

Publications

  1. ncbi Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8
    Minoru Kidokoro
    Department of Virology III, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama, Tokyo 208 0011, Japan
    Proc Natl Acad Sci U S A 102:4152-7. 2005
  2. ncbi Characterization of mumps viruses circulating in Mongolia: identification of a novel cluster of genotype H
    Minoru Kidokoro
    Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan
    J Clin Microbiol 49:1917-25. 2011
  3. ncbi MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy
    Mina Hikichi
    Core Facility for Therapeutic Vectors, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Mol Ther 19:1107-15. 2011
  4. ncbi SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus
    Masahiro Kitabatake
    Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113 8613, Japan
    Vaccine 25:630-7. 2007
  5. ncbi Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors
    Minoru Kidokoro
    Department of Research and Development, Chiba Serum Institute, 2 6 1 Kohnodai, Ichikawa, Chiba 272 0827, Japan
    Microbes Infect 4:1035-44. 2002
  6. ncbi [A new role of domestic small pox vaccine]
    Masanobu Sugimoto
    Tanpakushitsu Kakusan Koso 48:1693-701. 2003
  7. ncbi Development and biological properties of a new live attenuated mumps vaccine
    Shizuko Saika
    Chiba Prefectural Institute of Public Health, 666 2 Nitona cho, Chuo Ku, Chiba City, Chiba 260 8715, Japan
    Comp Immunol Microbiol Infect Dis 29:89-99. 2006
  8. ncbi Rescue system for measles virus from cloned cDNA driven by vaccinia virus Lister vaccine strain
    Yuichiro Nakatsu
    Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
    J Virol Methods 137:152-5. 2006

Collaborators

  • Masanobu Sugimoto
  • Mina Hikichi
  • Hisatoshi Shida
  • Masahiro Kitabatake
  • Michinori Kohara
  • Shizuko Saika
  • Yuichiro Nakatsu
  • Hideaki Tahara
  • Hideo Iba
  • Takeshi Haraguchi
  • Takafumi Nakamura
  • Kyosuke Mizuno
  • Shoji Yokochi
  • Kouichi Morita
  • Masaaki Arai
  • Fukashi Murai
  • Mai Quynh Le
  • Fumihiko Yasui
  • Kouji Matsushima
  • Shingo Inoue
  • Athuko Aoki
  • Hiroko Kubonoya
  • Kazuyoshi Suzuki
  • Kozo Ito
  • Noriyo Nagata
  • Yusuke Yanagi
  • Tokitada Ohkawa
  • Makoto Takeda

Detail Information

Publications8

  1. ncbi Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8
    Minoru Kidokoro
    Department of Virology III, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama, Tokyo 208 0011, Japan
    Proc Natl Acad Sci U S A 102:4152-7. 2005
    ..Our results suggest that this vaccine strain is a good candidate as a suitable smallpox vaccine and a vector virus, and that B5R is not essential for protective immunity against smallpox...
  2. ncbi Characterization of mumps viruses circulating in Mongolia: identification of a novel cluster of genotype H
    Minoru Kidokoro
    Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan
    J Clin Microbiol 49:1917-25. 2011
    ..However, the virus does not exhibit prominent neurovirulence in rats...
  3. ncbi MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy
    Mina Hikichi
    Core Facility for Therapeutic Vectors, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Mol Ther 19:1107-15. 2011
    ..These results demonstrate that miRNA-based gene regulation is a potentially novel and versatile platform for engineering vaccinia viruses for cancer virotherapy...
  4. ncbi SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus
    Masahiro Kitabatake
    Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113 8613, Japan
    Vaccine 25:630-7. 2007
    ..RVV-S can induce NT antibodies against SARS-CoV despite the presence of NT antibodies against VV. These results suggest that RVV-S may be a powerful SARS vaccine, including in patients previously immunized with the smallpox vaccine...
  5. ncbi Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors
    Minoru Kidokoro
    Department of Research and Development, Chiba Serum Institute, 2 6 1 Kohnodai, Ichikawa, Chiba 272 0827, Japan
    Microbes Infect 4:1035-44. 2002
    ..Such recombinant haemagglutinin preparations will be useful in diagnostic tests that measure functional anti-measles immunity and investigate the biological functions and structure of the haemagglutinin...
  6. ncbi [A new role of domestic small pox vaccine]
    Masanobu Sugimoto
    Tanpakushitsu Kakusan Koso 48:1693-701. 2003
  7. ncbi Development and biological properties of a new live attenuated mumps vaccine
    Shizuko Saika
    Chiba Prefectural Institute of Public Health, 666 2 Nitona cho, Chuo Ku, Chiba City, Chiba 260 8715, Japan
    Comp Immunol Microbiol Infect Dis 29:89-99. 2006
    ..Although the safety and immunogenicity should be confirmed in further field trials in humans, the present results indicate that the Y125 could be a promising vaccine candidate...
  8. ncbi Rescue system for measles virus from cloned cDNA driven by vaccinia virus Lister vaccine strain
    Yuichiro Nakatsu
    Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan
    J Virol Methods 137:152-5. 2006
    ..This safer and more efficient system will facilitate further the genetic manipulation of measles virus in basic research and virus vector development...